Medicilon Presents Revolution Medicines with the "Excellence in Client Partnership Award"

BOSTON, , Oct. 31, 2026 /PRNewswire/ -- Dr. Yang Liu, Director of Medicinal Chemistry at Revolution Medicines, Inc., and Dr. Kristof Pota, Senior Scientist, visited Medicilon's Nanhui R&D Center. Dr. Maosheng Duan, President of Medicilon's Drug Discovery and Pharmaceutical Research Divisions, Dr. Jian Wang, Vice President of Medicilon, and their team welcomed them. The two parties held in-depth discussions on project progress, data transfer, and strategic priorities for the coming year. During the visit, Medicilon presented Revolution Medicines with the "Excellence in Client Partnership Award," recognizing the substantial clinical value of the company's pioneering pan-KRAS drug discovery and development. The award also honors years of joint effort, mutual trust, and shared success by both R&D teams, setting an outstanding example of bilateral collaboration.

A Three-Year Partnership Built on a Trusted R&D Model

Over the past three years, Medicilon's FTE team has worked closely with Revolution Medicines to tackle R&D technical challenges, consistently prioritizing client needs and focusing on the single objective of efficiently delivering high-quality molecules. This partnership has established a model of mutual trust and robust CRO–client collaboration.

At the award ceremony, Dr. Duan commended Revolution Medicines for its pioneering work in advancing KRAS—a target once deemed "undruggable"—and congratulated the company on the U.S. FDA's August 2026 approval of the NDA for Daraxonrasib for metastatic pancreatic cancer. This milestone offers new hope for pancreatic cancer patients and delivers significant clinical value. The Excellence in Client Partnership Award recognizes the trust, dedication, and achievements of both teams over more than three years of collaboration, reflecting Medicilon's confidence in a deeper, long-term partnership.

In-Depth Discussions Explore New Collaboration Opportunities

During the discussions, Dr. Wang outlined Medicilon's growth and its integrated R&D platform spanning target discovery to IND submission. Medicilon's quality system meets international standards and holds NMPA, OECD GLP, FDA GLP, and AAALAC accreditation. Its advanced platforms support ADC/AOC, TPD, RIPTAC, RNAi, and peptide programs. Both parties discussed cross-regional data transfer, project management, future collaboration, and ways to enhance cross-border R&D efficiency.

Laboratory Tour

Subsequently, Drs. Liu and Pota toured Medicilon's R&D laboratories, visiting the chemistry and oligonucleotide labs as well as the API and preclinical research facilities, gaining firsthand insight into Medicilon's R&D infrastructure and quality management system.

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

Medicilon Presents Revolution Medicines with the "Excellence in Client Partnership Award"

MACAO, Oct. 30, 2026 /PRNewswire/ -- On October 30, the 16th China (Macau) International Automobile Exposition opened at The Venetian Macao's Cotai Expo. Under the theme "Where Craft Meets Technology," GAC presented multiple new-energy models. The GAC ALL-NEW E8 was officially launched in Macao, while the AION i60 and AION N60 made their Macao debuts. As the only Chinese automotive brand to have participated in the Macao Auto Expo for 16 consecutive years, GAC continues its "In Macao, For Macao" commitment, with sales in Macao up 113% year-on-year this year.

In product terms, GAC showcased an all-star lineup including the GAC ALL-NEW E8, GAC ALL-NEW M8, AION i60, AION N60, AION UT, AION V and GAC E9 PHEV, covering battery-electric, plug-in hybrid and extended-range powertrains, as well as sedans, SUVs and MPVs. In sales and service, GAC places GAC CARE+ at the core, supporting users from vehicle selection and purchase to use and maintenance. It has a showroom presence in Macao and offers the "Bay Area Link" service for maintenance across the Greater Bay Area, backed by the unified "One GAC" network. The GAC Owner APP enables one-tap vehicle control, and more service showrooms are planned. GAC also connects with users through global sports marketing, partnering with clubs including Chelsea FC Men, Villarreal CF and Flamengo to share a passion for football.

Designed for families in Macao and the Greater Bay Area, the GAC ALL-NEW E8 offers a pure-electric range of 281 km, charge-sustaining fuel consumption as low as 3.98 L/100 km, approximately 56 square feet of cabin space with 18 seating configurations, a 540° panoramic surround-view camera system, and a CLTC combined range of 1,537 km. The MAX variant is priced at HKD 339,800 and the ULTRA at HKD 369,800, with an early-bird discount of HKD 6,000.

Regionally, GAC's retail sales in Asia-Pacific rose 109% year-on-year in the first three quarters. In September, retail sales in Portugal grew 34% month-on-month, while Brazil surged 280% year-on-year. As a gateway to Portuguese-speaking markets, Macao plays a key role in GAC's global layout. Looking ahead, GAC will continue its long-term commitment to Macao, enhance local products and services, and deepen collaboration with Portuguese-speaking and Asia-Pacific markets.

For further information about GAC, please visit: https://www.gacgroup.com/en or follow us on social media.

 

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

GAC Showcases GAC ALL-NEW E8 at 2026 Macao Auto Expo